Skip to main content

Table 1 Main characteristics and results of the eligible studies

From: Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases

First authorYearCountryStudy typeNClinical stageChemotherapy regimenpCR rateFollow-up (median) (year)HR estimationOutcomes
Clifton2018USAProspective319I–IIA/T0.5386.33Survival curveOS, DFS
Fisher2012USARetrospective385I–IIINA0.172.5Survival curveOS
Kennedy2010USARetrospective405I–IIINANR4.3Survival curveOS
Sharma2015USARetrospective146I–IIA/TNR3.08Given by authorDFS
Cheng2017NRRetrospective15,483I–IIINANR2Given by authorOS
Yang2018ChinaProspective67II–IIIA/T0.1946.5Given by authorOS
Biswas2017USARetrospective420I–IIIA/T0.333.9Survival curveOS
Bagegni2019USARetrospective19,151II-IIINA0.4742.5Survival curveOS
Philipovskiy2019USARetrospective104I–IIIA/T0.46Given by authorOS,DFS
  1. NR not reported, A/T adriamycin/taxane, OS overall survival, DFS disease-free survival